Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Chapman, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Chapman, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Beyond LDL-cholesterol reduction: the way ahead in managing dyslipidaemia

John Chapman*

National Institute for Health and Medical Research, Hôpital de la Pitié, 83, boulevard de l'hopital, 75651 Paris, Cedex 13, France

* Corresponding author. Tel: +33 1 45 82 81 98; fax: +33 1 45 82 81 98. E-mail address: chapman{at}chups.jussieu.fr

Observational cohort studies and analysis of the populations of intervention trials at baseline reveal a strong inverse association between circulating levels of high-density lipoprotein (HDL)-cholesterol at baseline and the risk of a fatal or non-fatal cardiovascular event. Intervention with a statin is as effective, in absolute terms, in reducing the risk of coronary events in patients across a wide range of dyslipidaemic phenotypes, including those with low HDL-cholesterol. However, statins exert little effect on the levels of HDL-cholesterol, and treatment with a statin does not eliminate the excess risk associated with low HDL-cholesterol. Additional therapy is clearly required to address this residual risk. The success of clinical evaluations of agents that increase HDL-cholesterol, such as nicotinic acid or fibrate drugs, in reducing the incidence of cardiovascular events points to a way forward. Evidence from outcome studies already points to superior cardiovascular risk reductions in patients receiving a statin plus nicotinic acid, and intensive multi-drug regimens based on such combinations probably represent the way to achieve cardiovascular risk reductions greater than those possible with a statin alone. Accurate and well-validated assays for measuring HDL-cholesterol and more precise definition of optimal levels of HDL-cholesterol in patients with different levels of cardiovascular risk are required. These advances will facilitate the future drafting of guidelines that include correction of low HDL-cholesterol alongside reduction of low-density lipoprotein cholesterol within clinical algorithms for reducing cardiovascular risk.

Key Words: HDL-cholesterol • Atherosclerosis • Cardiovascular risk • Dyslipidaemia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.